Although antiretroviral therapies are the standard of care treatment for those with HIV, the drugs cannot target latent infections; however, venetoclax, a blood cancer treatment, shows promise.
An existing blood cancer drug has shown promise in killing 'silent' HIV cells and delaying reinfection, which could lead to a future cure for the disease.